Literature DB >> 9339846

The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism.

T Morikita1, Y Maeda, S Fujii, S Matsushita, K Obaru, K Takatsuki.   

Abstract

A primary isolate (KMT) of human immunodeficiency virus type 1 (HIV-1) resistant to recombinant soluble CD4 (rsCD4) was isolated from an HIV-1-infected individual and grown in a T lymphoid cell line. KMT isolate passaged on CEM cells (KMT/CEM) was still resistant to rsCD4. The V1/V2 and V3 regions of the viral envelope glycoprotein are thought to be involved in various biological phenotypes. To determine the exact envelope region of the KMT isolate responsible for sensitivity to rsCD4 and cellular tropism, we performed sequence analysis of KMT and KMT/CEM isolates. Sequence analysis of the KMT isolate showed that the sequence of the V3 region was relatively homogeneous, whereas a considerable heterogeneity of the V1/V2 region was noted. In contrast, the sequences of the V1 to V3 regions were homogeneous in KMT/CEM isolates. Analysis of NL4-3-based recombinant viruses with amplified sequences of the V1 to V3 regions from KMT and KMT/CEM isolates showed that the V1/V2 region modulated the sensitivity to rsCD4. A change in resistance to rsCD4 by the V1/V2 region was associated with the ability of the isolate to replicate in macrophages and efficiently replicate in T lymphoid cell lines. A change to an isolate sensitive to rsCD4 was associated with reduced replication efficiency in T lymphoid cell lines. Our results suggest that the V1/V2 region is involved in modulating the sensitivity to rsCD4, macrophage tropism, and replication efficiency in T lymphoid cell lines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9339846     DOI: 10.1089/aid.1997.13.1291

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  21 in total

1.  Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Authors:  Shi-Hua Xiang; Peter D Kwong; Rishi Gupta; Carlo D Rizzuto; David J Casper; Richard Wyatt; Liping Wang; Wayne A Hendrickson; Michael L Doyle; Joseph Sodroski
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

2.  The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.

Authors:  Abraham Pinter; William J Honnen; Paul D'Agostino; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

3.  Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.

Authors:  Junji Shibata; Kazuhisa Yoshimura; Akiko Honda; Atsushi Koito; Toshio Murakami; Shuzo Matsushita
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

4.  The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.

Authors:  Cheryl J Saunders; Ruth A McCaffrey; Irina Zharkikh; Zane Kraft; Susan E Malenbaum; Brian Burke; Cecilia Cheng-Mayer; Leonidas Stamatatos
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.

Authors:  Y Maeda; M Foda; S Matsushita; S Harada
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domains.

Authors:  J T Shieh; J Martín; G Baltuch; M H Malim; F González-Scarano
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.

Authors:  Cécile Tremblay; Isabelle Hardy; Richard Lalonde; Benoit Trottier; Irina Tsarevsky; Louis-Philippe Vézina; Michel Roger; Mark Wainberg; Jean-Guy Baril
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

8.  Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop.

Authors:  Guiqing Hu; Jun Liu; Kenneth A Taylor; Kenneth H Roux
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

9.  Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Authors:  Rong Rong; Frederic Bibollet-Ruche; Joseph Mulenga; Susan Allen; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.

Authors:  Abraham Pinter; William J Honnen; Yuxian He; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.